Skip to content

Social Prescription and Lifestyles Modification to Reduce Glycemia in People With Prediabetes (PREDIBAL)

Social Prescription of Health Assets and Lifestyles Modification by Primary Care Nurses to Reduce Glycemia in People With Prediabetes: PREDIBAL Study -a Cluster-randomized Hybrid Effectiveness-implementation Type II Trial Protocol

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04328363
Acronym
PREDIBAL
Enrollment
232
Registered
2020-03-31
Start date
2020-10-31
Completion date
2022-12-01
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes

Brief summary

This study aims to evaluate the effectiveness and cost-utility of an intervention based on the social prescription of health assets to modify lifestyles and reduce blood glucose values in prediabetic patients in primary care nursing consultations. Multicentre, controlled and randomized (two different branches) clinical trial with 18 months of follow-up will be performed. The intervention group will receive a social prescription of health assets related to the practice of physical activity and healthy eating patterns in primary care nursing consultation.

Detailed description

No pragmatic clinical trial evaluating the effectiveness of prevention interventions has been performed to date. Social prescription is a useful health promotion strategy that facilitates the continuity of individual care. This randomized controlled trial aims to evaluate the effectiveness and cost-utility of an intervention based on the social prescription of health assets to modify lifestyles and reduce blood glucose values in prediabetic patients in primary care nursing consultations. Additional aims are to describe and assess barriers, motivations, and attitudes of patients with low adherence to the intervention and their association with social class and gender. Methods: Multicentre, controlled and randomized (two different branches) clinical trial with 18 months of follow-up will be performed. The randomization unit will be the primary healthcare center. The study will be conducted by nurses in 12 primary health care centers (PHC) of Mallorca in Spain that will be included and randomly allocated to intervention or control groups. Furthermore, the intervention will be delivered at the PHC level, which is considered the unit of analysis. At least 232 patients (116 per branch) will be recruited. Participants will be aged 25 to 75 years with altered fasting glucose levels (100-125 mg/dl) or with glycosylated hemoglobin (HbA1c) between 5.7 and 6.4%. The intervention will be carried out at three levels: community, group and individually. The intervention group will receive a social prescription of health assets related to the practice of physical activity and healthy eating patterns in primary care nursing consultation for 8 sessions during 12 months of follow-up. The Control group will follow the usual care recommendations. Data will be collected at baseline, 6, 12 and 18 months. Glycaemia, HbA1c, BMI and waist circumference will be measured, as well as the Mediterranean diet adherence (PREDIMED), the physical activity (IPAQ), the cardiovascular risk (REGICOR equation), the quality of life (EuroQoL-5D), the social class, gender, and financial costs. .

Interventions

BEHAVIORALIntervention

Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.

Sponsors

University of the Balearic Islands
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Fasting basal blood glucose levels between 100 and \< 126 mg/dl or HbA1c between 5.7 - 6.4%

Exclusion criteria

* Patients with T2D or in treatment with oral antidiabetic drugs * Institutionalized patients * Terminal illness, dementia or cognitive impairment; * Pregnancy * Surgery or hospital admission in the previous 3 months * Hematological diseases that could interfere in HbA1c determination * Presence of any condition that limits the participation in the study * Participation in a clinical trial or receive a social prescription of diet or physical activity.

Design outcomes

Primary

MeasureTime frameDescription
Glucosa level18 monthThe primary outcome will be the percentage of participants reducing at least 4 mg/dl of FPG

Secondary

MeasureTime frameDescription
Reversion to normal glucose18 monthPercentage of patients who reverse to normal glucose levels

Contacts

Primary ContactAina M Yanez, PhD
aina.yanez@uib.es+34 971172914
Backup ContactMiquel Bennasar, PhD
miquel.bennasar@uib.es+34 971172367

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026